Search Results

You are looking at 1 - 10 of 100 items for :

  • "Chronic myeloid leukemia" x
Clear All
Full access

Jerald P. Radich, Michael Deininger, Camille N. Abboud, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Peter Curtin, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Madan Jagasia, Hagop M. Kantarjian, Lori Maness, Leland Metheny, Joseph O. Moore, Arnel Pallera, Philip Pancari, Mrinal Patnaik, Enkhtsetseg Purev, Michal G. Rose, Neil P. Shah, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory and Hema Sundar

Chronic myeloid leukemia (CML) accounts for 15% of adult leukemias. The median age of disease onset is 67 years; however, CML occurs in all age groups (SEER statistics). In 2018, an estimated 8,430 people will be diagnosed with CML in the United States

Full access

Merav Bar and Jerald Radich

Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia, 2012 Before the introduction of the tyrosine kinase inhibitors (TKIs), allogeneic hematopoietic cell transplantation (HCT) was the only “curative” approach for chronic myeloid

Full access

Ellin Berman

Among the challenges of treating women with chronic myeloid leukemia (CML) who may want to become pregnant is the lack of clear information regarding the dose of tyrosine kinase inhibitors (TKIs) and the exposure time. “The concept of stopping

Full access

Arnel Pallera, Jessica K. Altman, Ellin Berman, Camille N. Abboud, Bhavana Bhatnagar, Peter Curtin, Daniel J. DeAngelo, Jason Gotlib, R. Tanner Hagelstrom, Gabriela Hobbs, Madan Jagasia, Hagop M. Kantarjian, Patricia Kropf, Leland Metheny, Joseph O. Moore, Evelena Ontiveros, Enkhtsetseg Purev, Albert Quiery, Vishnu V.B. Reddy, Michal G. Rose, Neil P. Shah, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Raoul Tibes, David T. Yang, Kristina Gregory, Hema Sundar, Michael Deininger and Jerald P. Radich

this activity, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Chronic Myeloid Leukemia Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Chronic

Full access

Jorge Cortes, John M. Goldman and Timothy Hughes

BELA (Bosutinib Efficacy and safety in chronic myeloid LeukemiA) trial compared bosutinib with imatinib as front-line therapy in newly diagnosed CP-CML. 55 Although efficacy was comparable for patients who stayed on-study, the trial did not meet the

Full access

Michael W. Deininger, Neil P. Shah, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Lori Maness, Monica Mead, Leland Metheny, Sanjay Mohan, Joseph O. Moore, Kiran Naqvi, Vivian Oehler, Arnel M. Pallera, Mrinal Patnaik, Keith Pratz, Iskra Pusic, Michal G. Rose, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory and Hema Sundar

Overview Chronic myeloid leukemia (CML) accounts for 15% of adult leukemias. The median age of disease onset is 67 years; however, CML occurs in all age groups (SEER statistics). In 2020, an estimated 8,450 people will be diagnosed with CML in the

Full access

Alejandro Garcia-Horton and Jeffrey H. Lipton

The prognosis of chronic myeloid leukemia (CML) has greatly improved since the clinical use of tyrosine kinase inhibitors (TKIs) started with imatinib in the early 2000s. 1 It is now considered a chronic disease, with its incidence being stable

Full access

Neil P. Shah

Discontinuation of tyrosine kinase inhibitor (TKI) therapy appears to be safe among adult patients with chronic myeloid leukemia (CML) in the chronic phase who have achieved and maintained a deep molecular response (DMR), according to the updated

Full access

Henry J. Henk, Lena E. Winestone, Jennifer J. Wilkes, Laura Becker, Pamela Morin, Gary H. Lyman and Eric J. Chow

Background: Chronic myeloid leukemia (CML) treatment improved considerably after introduction of oral tyrosine kinase inhibitors (TKI). As a result, the number of patients living with CML may reach 250,000 by 2040. We track changes in TKI treatment

Full access

David D. Stenehjem, Frederick Albright, Kuan-Ling Kuo, Karina Raimundo, Hillevi Bauer, Paul J. Shami, Michael W. Deininger, Lei Chen and Diana I. Brixner

-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia . N Engl J Med 2003 ; 348 : 994 – 1004 . 2. Druker BJ Guilhot F O’Brien SG . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia . N Engl J Med